Table 3.
Active histone deacetylase inhibitors clinical trialsa
| HDACi | Combination drug(s) | Indication |
|---|---|---|
| Vorinostat | Azacitidine, bortezomib, decitabine, docetaxel, 5-FU, doxorubicine, idarubicin, erlotinib, isotretinoin, gemcitabine, temozolomide, sorafenib, tamoxifen, flavopiridol, paclitaxel/bevacizumab, paclitaxel/carboplatin, gemcitabine/cisplatin or carboplatin, 5-FU/leucovorin calcium/oxaliplatin, isotretinoin/carboplatin, cytarabine/etoposide, irinotecan/5-FU/leucovorin, rituximab/ifosfamide/carboplatin/etoposide, radical prostatectomy, palliative radiotherapy | CTCL, GBM, RCC, MDS, AML, ALL, CML, breast cancer, NSCLC, melanoma, lymphoma, advanced malignant pleural mesothelioma, advanced solid tumors, gliomas, nasopharyngeal cancer or nasal natural killer T-cell lymphoma, multiple myeloma, NHL, leukemia, colorectal cancer, GI cancer, prostate cancer, pelvic malignancy |
| Romidepsin | Decitabine, flavopiridol, gemcitabine, bortezomib | CTCL, PTCL, squamous cell carcinoma of the head and neck, NHL, refractory thyroid cancer, pulmonary and pleural malignancies, pancreatic, advanced solid tumors, relapsed myeloma, advanced lung, esophageal or pleural cancer |
| Belinostat | Azacitidine, bortezomib, isotretinoin, carboplatin/paclitaxel | Hepatocellular carcinoma, primary peritoneal cancer, fallopian tube cancer, B-cell NHL, T-cell lymphomas, MDS, thymic carcinoma, advanced hematological cancers, advanced solid tumors, lymphomas, ovarian cancer |
| LBH589 | Ketoconazole, bortezomib, trastuzumab, dextromethorphan, gemcitabine, lenalidomide/dexamethasone, capecitabine/lapatinib, paclitaxel/carboplatin/bevacizumab | CTCL, CML, MDS, NSCLC, advanced hematological malignancies, clear cell renal carcinoma, advanced solid tumors, multiple myeloma, breast cancer, malignant pleural mesothelioma |
| SB939 | None | Advanced or metastatic solid tumors |
| ITF2357 | None | Relapsed/refractory Hodgkin’s lymphoma |
| PCI-24781 (CRA-024781) | None | Advanced cancer |
| SNDX-275 | Azacitidine, erlotinib, sargramostim (GM-CSF), exemestane | NSCLC, AML, CML, MDS, breast cancer |
| MGCD0103 | Azacitidine, docetaxel, gemicitabine | AML, MDS, CLL, lymphoma, solid tumors, Hodgkin’s lymphoma, NHL |
| VPA | Decitabine, bevacizumab, doxorubicin, etoposide, epirubicin, sunitinib, sorafenib, dasatinib, erlotinib, lapatinib, lenalidomide, karenitecin, azacitidine/carboplatin, azacitidine/ATRA, ATRA/theophyllamine, FEC 100 (5-FU, epirubicin, and cyclophosphamide), temozolomide/radiation therapy | CLL, AML, MDS, GBM, small lymphocytic lymphoma, advanced thyroid cancer, nasopharyngeal carcinoma, ovarian cancer, NHL, advanced solid tumors, melanoma, advanced breast cancer, malignant mesothelioma, neuronal tumors and brain metastases |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CML, chronic myelogenous leukemia; CTCL, cutaneous T-cell lymphoma; EOC, epithelial ovarian cancer; 5-FU, 5-fluorouracil; GBM, glioblastoma multiforme; GI, gastrointestinal; HDACi, histone deacetylase inhibitors; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; NSCLC, nonsmall cell lung cancer; PTCL, peripheral T-cell lymphoma; RCC, renal cell carcinoma; VPA, valproic acid.
a
Further information regarding these clinical trials can be found at (http://www.cancer.gov/search/SearchClinicalTrialsAdvanced.aspx).